1 Treating COVID

This article may be...

Benefits of Vitamin D suplementation for corona virus. Why do we need a vaccine when we have Vitamin D?

See Andrew's free Vitamin Series at http://www.VitaminMasterclass.com/yt

Christiane Northrup, April 16, 2021 What's in Covid vaccine? More on Dr Northrup "Christiane Northrup, M.D., is a visionary pioneer and a leading authority in the field of women’s health and wellness, which includes the unity of mind, body,…

Nitric oxide (NO) is a free radical playing an important pathophysiological role in cardiovascular and immune systems. Recent studies reported that NO levels were significantly lower in patients with COVID-19, which was suggested to be closely related to vascular dysfunction and immune inflammation …

Yale University is conducting a study to figure out how to best create effect "messaging" in order to convince Americans to take the upcoming C0VlD vaccine.  In reality, their methods are nothing short of manipulation.  We break them down in detail. Check out our NEW Free Speech Platform https://ISE.Media ---------------- Support Truth in Media by visiting our sponsors: ISE.Media https://ISE.Media Pulse Cellular: Use code "TRUTH" for 10% every plan for life. https://truthinmedia.com/phone Pure VPN: Military grade vpn protection. https://truthinmedia.com/vpn Brave Browser: Open source and built by a team of privacy focused, performance oriented pioneers of the web. https://truthinmedia.com/brave #benswann

Click here to subscribe - https://www.glutenfreesociety.org/wxrn Quercetin is a bioflavonoid. It's a plant based product or chemical that has antiinflammatory properties on that enzyme. Quercetin can have a very nice antiinflammatory effect if you're taking it prophylactically. There's actually research studies that show quercetin has antiviral properties,and that quercetin actually can reduce the risk of developing upper airway diseases, upper respiratory tract infections and things of that nature. Quercetin also blocks the cycle oxygen ACE enzyme. That's why a lot of scientists are focusing in on quercitin as a potential. I wouldn't recommend quercitin to block the COX enzyme to reduce a fever because it doesn't work quite that way. Quercitin is not going to have that acute fever reducing capacity, but it is going to have that that overall reduction in overall inflammatory capacity. Then why do we want to know about this as it relates to any virus? Well, the research shows that quercetin through its effect on inflammation, can inhibit viral replication in multiple different areas. It's been very, very powerful as a nutrient in regards to immune function. So a lot of you have asked me, because vitamin C is very scarce right now, what can I use if I want to support my immune system right now? What can I use instead of vitamin C? I just can't find any vitamin C. Well, one of the things you can use is quercetin. Quercetin is very, very good at a lot of the things that vitamin C is good at. And because of its antiviral properties, it's actually been studied to be antiviral against the rhinovirus, against influenza, against the hepatitis virus, against Ebola virus. So there are a number of research studies that show that course it's in has very potent antiviral effects. Coronavirus resource page: https://www.glutenfreesociety.org/viral-outbreaks ** The products, supplements, vitamins, minerals, herbs, etc mentioned in these videos and article are not intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. There currently are no vaccines, pills, potions, lotions, lozenges or other prescription or over the-counter products available to treat or cure coronavirus disease 2019 (COVID-19) The information in these videos, and article is provided for educational purposes and should not be construed as medical advice. If you are seeking medical advice in regards to COVID-19 please visit the WHO website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

Norovirus is the leading cause of nonbacterial foodborne disease outbreaks. Human noroviruses (HuNoVs) bind to histo-blood group antigens as the host receptor for infection. In this study, the inhibitory effects of fucoidans from brown algae, Laminaria japonica (LJ), Undaria pinnatifida and Undaria pinnatifida sporophyll, were evaluated against murine norovirus (MNoV), feline calicivirus (FCV) and HuNoV. Pretreatment of MNoV or FCV with the fucoidans at 1 mg/mL showed high antiviral activities, with 1.1 average log reductions of viral titers in plaque assays. They also showed significant inhibition on the binding of the P domains of HuNoV GII.4 and GII.17 to A- or O-type saliva and the LJ fucoidan was the most effective, reaching 54–72% inhibition at 1 mg/mL. In STAT1−/− mice infected with MNoV, oral administration of the LJ fucoidan, composed of mainly sulfated fucose and minor amounts of glucose and galactose, improved the survival rates of mice and significantly reduced the viral titers in their feces. Overall, these results provide the LJ fucoidan can be used to reduce NoV outbreaks.

Watch Donate To Ican Coronavirus LIVE FROM ‘EVENT 2021’ IN DALLAS, TX MEDIA CAUGHT LYING ABOUT LONDON MEGA-RALLY TROUBLING SCIENCE EMERGING ON SPIKE PROTEIN 117 EMPLOYEES SUE HOSPITAL OVER VACCINE MANDATE Del is back! TOMORROW on The HighWire, June 3rd, 2021! HEART INFLAMMATION IN YOUTH RECENTLY VAXXED OSHA TURNS BLIND EYE TO VACCINE INJURY CDC… Read More »Watch

My work to help people is to educate them to use ICU and emergency room natural medicines to make them stronger. It surprises people to discover that substances like magnesium, sodium bicarbonate, iodine, selenium, and even vitamin C and D, when used at high dosages, are employed by doctors to save peoples’ lives in critical... View Article

Importance No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results Univariate analysis showed lower mortality in the ivermectin group (15.0% versus 25.2%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings should be further evaluated with randomized controlled trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial n/a ### Funding Statement No funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study was approved by the Broward Health IRB All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-dentified data is available upon request and approval by the Broward Health IRB.

People are dying, but what are they dying from? Is it an all-powerful virus that is doing hundreds of thousands of people in, or is it medical ignorance and medical malpractice? Ignorance is deadly in medicine and is usually sourced in arrogance and pharmaceutical greed and power, which is in full view with the American... View Article

Importance No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results Univariate analysis showed lower mortality in the ivermectin group (15.0% versus 25.2%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings should be further evaluated with randomized controlled trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial n/a ### Funding Statement No funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study was approved by the Broward Health IRB All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-dentified data is available upon request and approval by the Broward Health IRB.

Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.

Antiparasitic Drug Ivermectin Has Remarkable Anti-Cancer Activity.

Ivermectin has been repurposed as highly effective antiviral drug. Sadly, this is being ignored by US Medicine.

Challenge-Rechallenge Data from Switzerland reveals Efficacy of Hydroxyxhloroquine Against Corona Virus.

Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19.